MPM and Long­wood-backed Were­wolf Ther­a­peu­tics grabs $56 mil­lion to take tu­mors by night

Backed with the team from his last com­pa­ny, one of the key de­vel­op­ers be­hind Keytru­da has a new warch­est in the race to bring im­munother­a­py in­to the tu­mor mi­cro-en­vi­ron­ment.

Dan Hick­lin, who over­saw Mer­ck’s I/O port­fo­lio and helped de­vel­op sev­er­al oth­er can­cer drugs, is the founder and pres­i­dent of Were­wolf Ther­a­peu­tics, a com­pa­ny that aims to “shapeshift” its way in­to tu­mors and tear them apart from with­in. With the ex­cep­tion of the COO, its lead­er­ship is en­tire­ly seed­ed from Poten­za Ther­a­peu­tics, the an­ti­body com­pa­ny Hick­lin sold to Astel­las for $165 mil­lion up­front last De­cem­ber. They’ll even use the same lab space.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER